Prospects for Monoclonal Antibody Therapy in Pediatric Asthma

  • August Generoso
  • Christine Muglia-Chopra
  • John OppenheimerEmail author
Pediatric Allergy and Immunology (W Dolen, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pediatric Allergy and Immunology


Purpose of Review

The profile of biologic therapies for asthma is growing rapidly. We discuss how to match the proper pediatric patient with the most effective therapy.

Recent Findings

Currently available biologic therapies are most effective in patients with T2 high asthma. Newer drugs are currently being studied which target TSLP and interleukin 33. These newer drugs may provide options for asthmatics who do not respond to the current anti-IgE, anti-IL5, and anti-IL4/13 therapies.


Asthma is a heterogeneous disease which can be driven by different inflammatory mediators in different patients. To select the most effective biologic therapy for a pediatric patient, the asthma phenotype must first be determined. The steep cost of biologics limits their use, which makes proper pairing of patient to therapy even more crucial. Presently, several therapies exist for T2 high asthma, but it is hoped in the future that development of drugs effective for T2 low asthmatics will be available as well.


Asthma Children Pediatrics Biologic therapy T2 high 


Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Guilbert TW, Bacharier LB, Fitzpatrick AM. Severe asthma in children. J Allergy Clin Immunol Pract. 2014;2(5):489–500. Scholar
  2. 2.
    Patel TR, Sur S. IgE and eosinophils as therapeutic targets in asthma. Curr Opin Allergy Clin Immunol. 2017;17(1):42–9. Scholar
  3. 3.
    Centers for Disease Control and Prevention. Asthma. 2018. Accessed June 11, 2018.
  4. 4.
    Ramratnam SK, Bacharier LB, Guilbert TW. Severe asthma in children. J Allergy Clin Immunol Pract. 2017;5(4):889–98. Scholar
  5. 5.
    Centers for Disease Control and Prevention. Asthma-related missed school days among children aged 5–17 years. 2018. Accessed June 11, 2018.
  6. 6.
    Centers for Disease Control and Prevention. Asthma’s impact on the nation. Accessed June 11, 2018.
  7. 7.
    Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170(2):122–31. Scholar
  8. 8.
    Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001–8. Scholar
  9. 9.
    Panettieri RA Jr. Neutrophilic and pauci-immune phenotypes in severe asthma. Immunol Allergy Clin N Am. 2016;36(3):569–79. Scholar
  10. 10.
    Anderson WC 3rd, Szefler SJ. New and future strategies to improve asthma control in children. J Allergy Clin Immunol. 2015;136(4):848–59. Scholar
  11. 11.
    • Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA, et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc. 2017;38(4):250–63. Provided literature review of efficacy and safety of omalizumab, based on randomized control trials and real world studies. CrossRefPubMedGoogle Scholar
  12. 12.
    • Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–44. Provided literature review of efficacy and safety of omalizumab, based on randomized control trials and real world studies. CrossRefPubMedGoogle Scholar
  13. 13.
    Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26(6):551–6. Scholar
  14. 14.
    Xolair (omalizumab) Package Insert. 2017.Google Scholar
  15. 15.
    Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.CrossRefPubMedGoogle Scholar
  16. 16.
    Lemanske RF Jr, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics. 2002;110(5):e55.CrossRefPubMedGoogle Scholar
  17. 17.
    Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–15. Scholar
  18. 18.
    • Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clinical Immunol. 2015;136(6):1476–85. Described the potential efficacy of seasonal use of omalizumab CrossRefGoogle Scholar
  19. 19.
    Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–6. Scholar
  20. 20.
    Deschildre A, Marguet C, Salleron J, Pin I, Rittie JL, Derelle J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224–33. Scholar
  21. 21.
    Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K, et al. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol Int. 2015;64(4):364–70. Scholar
  22. 22.
    Deschildre A, Marguet C, Langlois C, Pin I, Rittie JL, Derelle J, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856–9. Scholar
  23. 23.
    Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604–9. Scholar
  24. 24.
    Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K, et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66(1):106–15. Scholar
  25. 25.
    Campbell JM, Wofford JD, Knutsen AP. Omalizumab treatment in children 6 to 18 years old with severe asthma at a children’s medical center. Pediatr Asthma Allergy Immunol. 2008;21(3):129–35.CrossRefGoogle Scholar
  26. 26.
    Steiss JO, Schmidt A, Nahrlich L, Zimmer KP, Rudloff S. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Allergy Asthma Proc. 2012;33(1):77–81. Scholar
  27. 27.
    Busse W, Humbert M, Stephenson P, Iqbal A, Trzaskoma B, Conde L, et al. The effect of omalizumab on lung function in adolescents with moderate-to-severe allergic asthma. Am J Respir Crit Care Med. 2017;195:A5105.Google Scholar
  28. 28. Preventing Asthma in High Risk Kids (PARK). 2018. Accessed June 11, 2018.
  29. 29.
    Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:Cd003559. Scholar
  30. 30.
    Blaiss MS, Castro M, Chipps BE, Zitt M, Panettieri RA Jr, Foggs MB. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma. Ann Allergy Asthma Immunol. 2017;119(6):533–40. Scholar
  31. 31.
    Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33(9):1605–13. Scholar
  32. 32.
    Nucala (mepolizumab) Package Insert. 2017.Google Scholar
  33. 33.
    Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (London, England). 2012;380(9842):651–9. Scholar
  34. 34.
    Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207. Scholar
  35. 35.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97. Scholar
  36. 36.
    • Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clinical therapeutics. 2016;38(9):2058–70.e1. Described the long-term efficacy and safety of mepolizumab in asthma, supporting the findings of the MENSA and SIRIUS studies by demonstrating maintenance of a lower OCS dose and lower asthma exacerbation rate. CrossRefPubMedGoogle Scholar
  37. 37.
    • Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. Showed that mepolizumab was associated with significant improvements in health-related quality of life. CrossRefPubMedGoogle Scholar
  38. 38.
    • Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810. Supported the prior findings that reslizumab did not result in clinically meaningful effects on lung function and symptom control in patients with baseline eosinophils < 400 cells/μL. CrossRefPubMedGoogle Scholar
  39. 39.
    Cinqair (reslizumab) Package Insert. 2016.Google Scholar
  40. 40.
    • Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66. Showed that reslizumab improved outcomes in patients with inadequately controlled asthma who had blood eosinophil count ≥ 400 cells/μL by decreasing annual rate of exacerbations and improving time to first exacerbation, FEV1, asthma control scores, and quality of life scores. CrossRefPubMedGoogle Scholar
  41. 41.
    • Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet (London, England). 2016;388(10056):2115–27. Showed that benralizumab reduced annual asthma exacerbation rates and improved lung function. CrossRefGoogle Scholar
  42. 42.
    • FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2016;388(10056):2128–41. Supported prior findings that Benralizumab significantly lowered exacerbation rates and improved FEV1. CrossRefGoogle Scholar
  43. 43.
    • Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–58. Showed the steroid-sparing effect of benralizumab. CrossRefPubMedGoogle Scholar
  44. 44.
    Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20. Scholar
  45. 45.
    • Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:Cd010834. This Cochrane review supported the use of anti-IL-5 biologics, finding that all three currently available agents reduced exacerbation rates by 50%. PubMedCrossRefGoogle Scholar
  46. 46.
    • Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; Showed that dupilumab reduced severe asthma exacerbations and improved lung function.
  47. 47.
    • Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018; Showed the steroid-sparing effect of dupilumab.
  48. 48.
    Hua F, Ribbing J, Reinisch W, Cataldi F, Martin S. A pharmacokinetic comparison of anrukinzumab, an anti-IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. Br J Clin Pharmacol. 2015;80(1):101–9. Scholar
  49. 49.
    Quirce S, Bobolea I, Dominguez-Ortega J, Barranco P. Future biologic therapies in asthma. Arch Bronconeumol. 2014;50(8):355–61. CrossRefPubMedGoogle Scholar
  50. 50.
    Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. J Mol Biol. 2017;429(2):208–19. CrossRefPubMedGoogle Scholar
  51. 51.
    Panettieri RA Jr, Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6:511–25. Scholar
  52. 52.
    Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–96. Scholar
  53. 53.
    He R, Geha RS. Thymic stromal lymphopoietin. Ann N Y Acad Sci. 2010;1183:13–24. Scholar
  54. 54.
    Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–46. CrossRefPubMedGoogle Scholar
  55. 55. Study to evaluate tezepelumab in adults & adolescents with severe uncontrolled asthma (NAVIGATOR). 2017. Accessed May 26, 2018.
  56. 56. Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE). 2018. Accessed May 26, 2018.
  57. 57.
    Li J, Saruta K, Dumouchel JP, Magat JM, Thomas JL, Ajami D, et al. Small molecule mimetics of alpha-helical domain of IRAK2 attenuate the proinflammatory effects of IL-33 in asthma-like mouse models. J Immunol (Baltimore, Md: 1950). 2018;200(12):4036–43. Scholar
  58. 58.
    Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, et al. IL-33 and its receptor ST2 after inhaled allergen challenge in allergic asthmatics. Int Arch Allergy Immunol. 2018;176(2):133–42. Scholar
  59. 59. Efficacy and safety study of GSK3772847 in subjects with moderately severe asthma. 2018.
  60. 60.
    GoodRx. Omalizumab. 2018. June 11, 2018.
  61. 61.
    Epocrates. Omalizumab. 2018. Accessed June 11, 2018.
  62. 62.
    van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ. 2013;16(3):342–8. Scholar
  63. 63.
    Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22(9):1765–76. Scholar
  64. 64.
    Campbell JD, McQueen RB, Briggs A. The “e” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc. 2014;11(Suppl 2):S105–11. Scholar
  65. 65.
    GoodRx. Mepolizumab. 2018. Accessed June 11, 2018.
  66. 66.
    Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–5. CrossRefPubMedGoogle Scholar
  67. 67.
    Draikiwicz S, Oppenheimer J. Use of biological agents in asthma: pharmacoeconomic lessons learned from omalizumab. Chest. 2017;151(2):249–51. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • August Generoso
    • 1
  • Christine Muglia-Chopra
    • 1
  • John Oppenheimer
    • 1
    Email author
  1. 1.Rutgers New Jersey Medical SchoolThe State University of New JerseyNewarkUSA

Personalised recommendations